Yongin-si, South Korea

Jun Sung Lee



Average Co-Inventor Count = 17.6

ph-index = 2

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2015-2016

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations in Diabetes Treatment: The Inventions of Jun Sung Lee

Introduction: Jun Sung Lee is an accomplished inventor based in Yongin-si, South Korea, known for his significant contributions to the field of pharmacology, particularly in the treatment of metabolic disorders like diabetes. With three patents to his name, Lee has made remarkable strides in the development of innovative compounds aimed at improving health outcomes for individuals affected by these conditions.

Latest Patents: Jun Sung Lee's latest patents focus on diphenylmethane derivatives as inhibitors targeting sodium-dependent glucose cotransporter 2 (SGLT2). His first patent describes a unique compound featuring a diphenylmethane moiety that demonstrates inhibitory activity against SGLT2, which plays a vital role in glucose reabsorption in the intestine and kidneys. This compound is designed as an active ingredient in pharmaceutical compositions that aim to prevent or treat metabolic disorders, particularly diabetes. Additionally, Lee has developed a method for dual inhibition of both SGLT1 and SGLT2 using these diphenylmethane derivatives, enhancing therapeutic efficacy for patients by simultaneously targeting both transporters.

Career Highlights: Jun Sung Lee is currently affiliated with The Green Cross Corporation, a leader in the biopharmaceutical industry known for its focus on developing innovative therapies for various diseases. His commitment to research and development in this competitive field highlights his dedication to finding solutions that can transform patient lives.

Collaborations: Throughout his career, Lee has collaborated with fellow researchers, including Soongyu Choi and Suk Ho Lee. Together, they explore groundbreaking approaches to enhance the effectiveness of diabetes treatments, solidifying their roles as key figures in the research community.

Conclusion: Jun Sung Lee's contributions to the field of diabetes treatment through his inventive work on diphenylmethane derivatives exemplify the importance of innovation in healthcare. As his patents suggest, his research not only addresses current metabolic disorders but also paves the way for future advancements in pharmacological therapies aimed at improving patients' quality of life.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…